ATC Group: B06AC01 C1-inhibitor, plasma derived

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B06AC01 in the ATC hierarchy

Level	Code	Title
`1`	B	Blood and blood forming organs
`2`	B06	Other hematological agents
`3`	B06A	Other hematological agents
`4`	B06AC	Drugs used in hereditary angioedema
`5`	B06AC01	C1-inhibitor, plasma derived

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	1,400 [iU]

Active ingredients in B06AC01

Active Ingredient
C1-inhibitor
C1 inhibitor is a single chain glycoprotein found in plasma and a member of the serine protease inhibitor, or serpin, superfamily of proteins. C1 inhibitor inhibits the complement system by binding C1r and C1s and is the most important inhibitor of contact activation, regulating the contact system and the intrinsic coagulation pathway by binding to and inactivating kallikrein and factor XIIa.